AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30683195
Drug: Best Endovascular
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Endovascular Therapy
Trial: 30683195
Drug: Best Surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Surgical Therapy
Trial: 20160062
Drug: PCV chemotherapy
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCV chemotherapy
Trial: 18657891
Drug: Serum phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum phosphorus level greater than 6 mg/dL
Trial: 18657891
Drug: Serum calcium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum calcium level greater than 11 mg/dL
Trial: 18657891
Drug: Ca x
RxNorm normalized name: Base PCCA Xylifos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca x P product greater than 50 mg(2)/dL(2)
Trial: 18657891
Drug: Intact parathyroid
RxNorm normalized name: Intact parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact parathyroid hormone levels
Trial: 10510219
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (221 +/- 18 mg; range 60-360 mg)
Trial: 10510219
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate 40 mg daily
Trial: 10510219
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate 60 mg every 3 months
Trial: 1763596
Drug: Ketamine 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.7 mg/kg BW i.v. before anaesthesia, and 0.35 mg/kg BW 15 and 30 min after the first dose
Trial: 1763596
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 mg/kg BW i.v. before anaesthesia
Trial: 31796519
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg IV every 21 days and Vorinostat 400 mg orally 5 days on and 2 days off during each 21-day cycle
Trial: 28983665
Drug: Prebiotic vaginal
RxNorm normalized name: Suppository, Multi Ingredient Vaginal Suppository [VH ESSENTIALS PREBIOTIC VAGINAL SUPPOSITORIES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic vaginal gel (5 mg) plus three 250 mg metronidazole tablets per day for 7 days
Trial: 28983665
Drug: Metronidazole tablet
RxNorm normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole tablet alone (three 250 mg tablets per day for 7 days)
Trial: 18041436
Drug: Glucomannan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan (1 g) before 75-g glucose load
Trial: 18041436
Drug: Glucomannan (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan (3 g/day for 4 weeks)
Trial: 9755295
Drug: Fleroxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (200 mg IV)
Trial: 9755295
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg IV)
Trial: 7823260
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aspirin (ASA) administered daily for two weeks
Trial: 3392236
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of loprazolam
Trial: 3392236
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of loprazolam
Trial: 30298608
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (ART at study enrollment)
Trial: 30298608
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment (ART when CD4 count fell below 350 cells/µL)
Trial: 25760804
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg once daily)
Trial: 25045726
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular injection of vitamin E + selenium 3 weeks prepartum
Trial: 25045726
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of oral vitamin E from 3 weeks prepartum to parturition
Trial: 25045726
Drug: Injective vitamin
RxNorm normalized name: vitamin A Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injective vitamin E + selenium with daily supplementation of oral vitamin E
Trial: 9131946
Drug: S-flurbiprofen (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-flurbiprofen (75 mg)
Trial: 9131946
Drug: R-flurbiprofen (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-flurbiprofen (75 mg)
Trial: 25547003
Drug: Intraperitoneal raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal raltitrexed in normal saline (500 ml)
Trial: 31931924
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (500 ml)
Trial: 20818903
Drug: Double-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose clopidogrel (600 mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter)
Trial: 20818903
Drug: Standard-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose clopidogrel (300 mg loading dose and 75 mg daily thereafter)
Trial: 20818903
Drug: Higher-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose aspirin (300 to 325 mg daily)
Trial: 20818903
Drug: Lower-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower-dose aspirin (75 to 100 mg daily)
Trial: 20818903
Drug: Higher-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher-dose aspirin
Trial: 20818903
Drug: Lower-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower-dose aspirin
Trial: 12663712
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (MACOP-B regimen)
Trial: 12663712
Drug: Abbreviated chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (HDT-ASCT)
Trial: 10362762
Drug: Men (M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men (M) and Women (W) matched by VO2 max (46.1 +/- 2.0 and 43.6 +/- 2.9 ml. kg‐1. min‐1)
Trial: 10362762
Drug: Men (MF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men (MF) with higher fitness level (VO2 max of 59.1 +/- 1.8 ml. kg‐1. min‐1)
Trial: 31567988
Drug: Sham electroacupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electroacupuncture treatment
Trial: 23560476
Drug: aqueous gel
RxNorm normalized name: Sulfacetamide Sodium/Sulfur 10%-5% Topical application Gel/Jelly [ROSULA AQUEOUS GEL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aqueous gel
Trial: 15351856
Drug: CYP2C9 genotyping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2C9 genotyping prior to initiation of warfarin therapy (genotyped group)
Trial: 9145846
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg single dose)
Trial: 9145846
Drug: Rufloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin (400 mg single dose)
Trial: 3595697
Drug: Diclofenac (preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (preoperative administration)
Trial: 3595697
Drug: Diclofenac (postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (postoperative administration)
Trial: 27566586
Drug: Endostar antiangiogenic
RxNorm normalized name: Menostar
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endostar antiangiogenic therapy combined with NP neoadjuvant chemotherapy
Trial: 27566586
Drug: NP neoadjuvant
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP neoadjuvant chemotherapy alone
Trial: 25070091
Drug: PA administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA administration
Trial: 23583327
Drug: RECOS (individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RECOS (individualized therapy)
Trial: 23583327
Drug: CRT (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT (general cognitive remediation therapy)
Trial: 16873785
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (immediately premeal)
Trial: 16873785
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (15 min postmeal)
Trial: 14655784
Drug: Clobetasol cream
RxNorm normalized name: clobetasol Topical Cream
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol cream 0.05% and solution 0.05%
Trial: 27128607
Drug: Mericitabine 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine 1,500 mg
Trial: 27128607
Drug: Mericitabine 9,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine 9,000 mg
Trial: 22187234
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (200 mg celecoxib and 20 mg doxycycline, both twice daily)
Trial: 22187234
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice daily) only
Trial: 21094838
Drug: High-dose antithymocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antithymocyte globulin (ATG) therapy plus shortened standard therapy (group 1)
Trial: 21094838
Drug: High-dose ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ATG therapy (group 1)
Trial: 17426325
Drug: MK-0557 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0557 (1 mg/d)
Trial: 7796643
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg twice daily for three months
Trial: 7796643
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg twice daily and cyclopentylethinyl estriol (CEE3) 5 mg once a month for three months
Trial: 2127789
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b treatment (3 million units, three times weekly, subcutaneously for 36 weeks)
Trial: 2127789
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b treatment
Trial: 28432265
Drug: Actovegin (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin (2000 mg/d for ≤20 intravenous infusions followed by 1200 mg/d orally)
Trial: 19593411
Drug: Adjunctive use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive use of denicotinized cigarettes
Trial: 11028571
Drug: Levonorgestrel-releasing (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel-releasing (20 μg/day) intrauterine system (LNG-20)
Trial: 9198052
Drug: Intradermal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Trial: 9198052
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Trial: 9198052
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of intradermal schedule
Trial: 1376843
Drug: Isradipine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 1.25 mg
Trial: 9848540
Drug: Metronidazole 250
RxNorm normalized name: metronidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 250 mg plus Amoxicillin 500 mg, 3 times/day for a week
Trial: 9848540
Drug: Metronidazole plus
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole plus Amoxicillin (M+A)
Trial: 8024227
Drug: Calcium nadroparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium nadroparin (fixed dose: daily subcutaneous injection of 0.6 ml, i.e. 6150 anti‐Xa IU, n = 38)
Trial: 8024227
Drug: Calcium nadroparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium nadroparin (weight-adjusted dose: 31.5 anti‐Xa IU/kg, n = 40)
Trial: 8024227
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg as a single daily dose, n = 39)
Trial: 1095134
Drug: Monofluorophosphate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monofluorophosphate (25 mg fluoride per day)
Trial: 7562730
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no fluoride treatment)
Trial: 31153674
Drug: Typical hypocaloric
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical hypocaloric dietary treatment
Trial: 31814707
Drug: AZD7594 (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7594 (1600 µg)
Trial: 28407543
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis (6.9% THC, ∼54mg)
Trial: 21689343
Drug: Patent blue
RxNorm normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patent blue V dye injection
Trial: 21689343
Drug: No patent
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No patent blue V dye injection
Trial: 21689343
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after application of Carnoy's solution
Trial: 16174897
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (EACA) 5 g infused during 1 hour, then 1 g/hour for 23 hours
Trial: 11928795
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (external beam and brachytherapy)
Trial: 9880769
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (not specified)
Trial: 11928795
Drug: Adjuvant doxorubicin-based
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant doxorubicin-based chemotherapy
Trial: 9788526
Drug: Alprazolam (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0, 1, 2 mg)
Trial: 9788526
Drug: d‐amphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine (0, 12.5, 25 mg)
Trial: 9788526
Drug: Codeine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (0, 60, 120 mg)
Trial: 9788526
Drug: Drug Recognition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Recognition Examiners (DREs) decisions
Trial: 9788526
Drug: Drug class
RxNorm normalized name: VARIOUS DRUG CLASSES IN ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug class decisions by DREs
Trial: 7697134
Drug: DMSA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA (10 mg/kg, oral)
Trial: 7697134
Drug: EDTA (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA (1 g, intravenous)
Trial: 2487304
Drug: Oral nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nitrofurantoin (100 mg t.i.d.) for five days
Trial: 2487304
Drug: Oral ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ampicillin (500 mg t.i.d.) for five days
Trial: 20124
Drug: Beta1-adrenoceptor selective
RxNorm normalized name: beta-Arbutin
DrugBank: Arbutin (DB11217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta1-adrenoceptor selective blocker (metoprolol)
Trial: 20124
Drug: Non-selective blockers
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective blockers (e.g., propranolol)
Trial: 31308592
Drug: Traditional BPB
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Trial: 31308592
Drug: Perpendicular BPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perpendicular BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Trial: 31308592
Drug: Axillary BPB
RxNorm normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axillary BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Trial: 25173085
Drug: IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT with dose constraints on the brachial plexus (BP) (maximum dose limit of ≤66 Gy)
Trial: 25173085
Drug: IMRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT with dose constraints on the BP
Trial: 11782868
Drug: Regular cow
RxNorm normalized name: Cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular cow milk protein-based formula with added cholesterol (RF+cholesterol) 3.44 mmol cholesterol/L (133 mg cholesterol/L)
Trial: 2748223
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (salbutamol)
Trial: 29292066
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of 5.0 ppm F milk once per day
Trial: 29292066
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 5.0 ppm F twice per day
Trial: 29292066
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml of 5.0 ppm F once every other day
Trial: 29292066
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (once per day, twice per day, once every other day)
Trial: 26864002
Drug: Intrathecal anaesthesia
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal anaesthesia with 40 mg intrathecal hyperbaric prilocaine
Trial: 26864002
Drug: Peripheral nerve
RxNorm normalized name: Peripheral nerve antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral nerve blockade with 25 ml mepivacaine 2%
Trial: 20169950
Drug: Rocuronium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.4 mg x kg(‐1)
Trial: 20169950
Drug: Rocuronium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.5 mg x kg(‐1)
Trial: 20169950
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg x kg(‐1)
Trial: 15694877
Drug: Electronic daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic daily diary assessment of pain-related variables
Trial: 1876742
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with 0.05 mg of fentanyl
Trial: 21532072
Drug: Systematic implementation
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic implementation of behavioral interventions including trauma-informed care training, changes to unit rules and language, changes to the physical characteristics of the therapeutic environment, and involvement of patients in treatment planning.
Trial: 18971549
Drug: Losartan (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (12.5 mg/d)
Trial: 18971549
Drug: Control (antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antiplatelet agents)
Trial: 16155076
Drug: rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 8 mg daily for 12 weeks
Trial: 16155076
Drug: rosiglitazone 2
RxNorm normalized name: rosiglitazone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 2 mg daily for 12 weeks
Trial: 16155076
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg daily for 12 weeks